Showing recent highlights
What's New
PubMed (Open Access Guidelines) · December 1, 2026
Researchers found that allergen immunotherapy — a treatment that gradually exposes the immune system to small amounts of a trigger like dust mites or grass pollen to reduce sensitivity — helped people with allergic asthma breathe better and rely less on medication. Shots (given under the skin) appeared to work better than drops or tablets placed under the tongue, and the treatment seemed to help both children and adults fairly equally. However, the shot-based approach did cause more whole-body reactions, like hives or swelling, so that's something patients would want to discuss with their doctor. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that delivering a protein called interferon-beta — which the body naturally uses to fight viruses — directly into the nose or lungs (through a spray or inhaler) may help the body better defend itself against respiratory viral infections. This is particularly interesting for people with asthma, because their airways often have a weaker natural antiviral response, which can make viral infections like colds or flu trigger more serious flare-ups. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that people with severe asthma who traveled to a high-altitude climate treatment program in Davos, Switzerland often felt better afterward — but those benefits tend to fade once they return home. The study looked at whether adding home monitoring devices (tools that measure breathing and airway irritation) to an online self-management program could help people hold onto those gains longer, and while there was a hint that the monitoring group had fewer serious asthma flare-ups and a slower decline in symptom control over the first six months, the difference wasn't large enough to be considered definitive. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that two simple, non-invasive tests — measuring a gas called nitric oxide in a person's breath (FeNO) and counting a type of immune cell in their blood (eosinophils) — can help doctors figure out whether someone has asthma, especially when standard breathing tests come back normal. This matters because diagnosing asthma can be tricky, and these tests are easier to access in a regular doctor's office than some of the more specialized breathing challenge tests currently used. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
A study found that when emergency department doctors were shown a simple summary of a child's asthma control — based on a short questionnaire parents filled out — they were about ten times more likely to refer that child to follow-up asthma care after leaving the ER, compared to doctors who didn't see the summary. This matters because kids who visit the ER for a serious asthma episode often go home without a plan for ongoing care, which can leave their asthma poorly managed. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that dupilumab, an injected medication that calms a specific type of airway inflammation, helped people with moderate-to-severe asthma in Latin America breathe better and have fewer serious asthma attacks over nearly three years of use. People who had been on a placebo and then switched to the medication also saw real improvements, suggesting the drug continued to work well over a long period. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
A study found that people with severe asthma who started a biologic injection treatment (a medication given by shot to reduce immune system overreactions) often became less consistent about using their daily inhalers over time — and those who used their inhalers less regularly tended to have worse asthma symptom control. This matters because even when someone is on an advanced treatment, keeping up with everyday inhaler use still appears to play an important role in how well their asthma is managed. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · November 1, 2026
A study found that tezepelumab (brand name Tezspire), an injected medication that works by blocking a protein in the immune system that can trigger asthma attacks, was examined in children aged 5–11 and teenagers aged 12–17 with asthma. Researchers found that the medication moved through the body in a similar way in younger children as it does in adults, and no new safety concerns were identified. This appears to be an early step toward potentially expanding the use of a treatment that is currently approved for teens and adults with severe asthma to younger children.
What's New
PubMed · November 1, 2026
Researchers found that a traditional Chinese herbal liquid medicine called Zhichuanling (ZCL) helped children with asthma breathe better and recover from symptoms more quickly when added to standard treatment — about 87% of children who received it showed meaningful improvement, compared to 60% in the group that got standard treatment alone. The medicine appeared to work by calming inflammation in the airways and reducing oxidative stress, which is a kind of cell damage caused by harmful molecules building up in the body. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that using a standard inhaler with a spacer (a tube that attaches to the inhaler to help get more medicine into the lungs) worked just as well as a nebulizer (a machine that turns liquid medicine into a mist) for treating sudden asthma attacks — with similar rates of hospital admission in both adults and children. In kids specifically, using the inhaler with a spacer was linked to shorter emergency room visits and less trembling or shaking, which can be a side effect of asthma rescue medicine. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 31, 2026
Researchers found that a common asthma treatment — a combination inhaler that contains two types of medication (one to reduce airway inflammation and one to keep the airways open) — works similarly in real-world patients as it does in carefully controlled research settings, which isn't always a given. This matters because sometimes treatments that look great in studies don't perform as well when used by everyday patients who may miss doses or have less frequent doctor check-ins. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 21, 2026
A study found that a procedure called bronchial thermoplasty — which uses gentle heat to reduce the thickness of airway muscles in the lungs, making it easier to breathe — helped people with severe, hard-to-control asthma feel better and manage their condition more effectively. However, researchers also found that people were more likely to need a hospital stay during the weeks when they were receiving the treatment, though that extra risk seemed to go away afterward. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 17, 2026
Researchers found that breathing in outdoor ozone — a type of air pollution formed when sunlight reacts with chemicals in the air — is linked to real harm to the lungs, more asthma flare-ups, and more emergency room visits, even when ozone levels are below the limits currently set by the EPA. People with asthma, children, and older adults appear to be hit the hardest, and the review even found that high ozone days are connected to kids missing more school due to breathing problems. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
A study found that people with asthma or COPD (a lung disease that makes breathing difficult) who came from lower-income backgrounds got significantly better care when a trained health coach worked alongside a lung specialist to support them — they received about 60% more guideline-based care compared to patients who got standard care alone. The health coach gathered information from the patient and shared it with a lung specialist, who then gave recommendations to the patient's primary care doctor, and the coach helped make sure those recommendations were actually followed. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
Researchers found that a simple five-question symptom checklist — asking people with asthma how often they wake up at night, how limited their activities are, and similar questions — can help predict who is likely to have a serious asthma attack in the future and who might respond best to anti-inflammatory treatments. Looking at data from over 7,000 people across multiple studies, they found that people reporting a heavier load of symptoms were more likely to experience dangerous flare-ups, suggesting that paying close attention to everyday symptoms could help doctors intervene earlier. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · October 1, 2026
A study found that a triple-combination inhaler called Trelegy Ellipta — which combines three medicines to help open the airways and reduce inflammation — helped more adults with hard-to-control asthma reach what researchers call 'clinical remission,' meaning their asthma became very well managed with fewer flare-ups and better breathing, compared to people using a standard two-medicine inhaler. This appears to be a newer treatment option being studied for people whose asthma isn't well controlled on their current medication. Researchers found the triple inhaler outperformed the standard approach after about a year of use.
Ask your doctor: Ask the doctor whether switching to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in a single inhaler might help the patient achieve better asthma control and remission compared to the patient's current ICS/LABA combination.
What's New
PubMed · October 1, 2026
Researchers found that people with asthma who experience symptoms at night — such as coughing, wheezing, or shortness of breath that wakes them up — tend to have more severe asthma overall, including worse lung function compared to those whose symptoms don't follow that nighttime pattern. This matters because nighttime symptoms could be an important signal that someone's asthma may need closer attention from their doctor. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
A study found that people with allergic asthma triggered by house dust mites who received a combination of omalizumab (a biologic injection that calms allergic responses) and allergy shots were more likely to reach clinical remission — meaning their asthma symptoms largely quieted down — than those who received either treatment alone, with about 47% of combination-therapy patients achieving this compared to around 14% on standard care. The combined approach also led to fewer serious flare-ups and less need for steroid medications over three years. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
Researchers found that depemokimab, a new injectable medication given less frequently than similar treatments, cut asthma flare-ups (episodes where symptoms suddenly get much worse) nearly in half in people with a type of asthma driven by an overactive immune response. However, it didn't clearly improve how patients felt day-to-day or their overall quality of life in a meaningful way. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
Researchers found that a new injectable antibody drug called MG-K10 helped people with moderate-to-severe asthma breathe more easily — specifically, it improved how much air they could forcefully exhale in one second, which is a standard measure of lung function. The improvement was even greater in people who had higher levels of a type of immune cell called eosinophils (white blood cells that, when elevated, often signal inflammation-driven asthma) in their blood. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · October 1, 2026
According to the Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology Joint Task Force, guidelines are being developed around the use of macrolides — a type of antibiotic — for people with asthma, based on a review of 19 studies involving over 1,800 patients. The review found that macrolides helped improve asthma control and likely reduced the number of severe asthma flare-ups compared to a placebo (a dummy treatment with no active medicine). This matters because better asthma control means fewer dangerous episodes, though patients should speak with their doctor about whether this type of treatment might be appropriate for their specific situation.
Ask your doctor: Ask the doctor whether macrolide antibiotics like azithromycin might help the patient's asthma control and reduce severe asthma flare-ups, and what the risks and benefits would be for the patient specifically.
What's New
PubMed · October 1, 2026
Researchers found that doctors who treat severe asthma don't all agree on what it means for a patient to be 'in remission' — that is, when their asthma is well enough controlled that it's causing little to no disruption to their life. A group of respiratory specialists worked together to create shared definitions for two key ideas: full remission (where symptoms are very well controlled) and a middle ground called 'minimal clinical disease activity,' which recognizes that some patients may not reach full remission but are still doing much better than before. Having clear, agreed-upon goals like these could help patients and their doctors track progress and aim for the best possible quality of life, not just fewer symptoms. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · October 1, 2026
A study found that dupilumab (brand name Dupixent), a medication given by injection every two weeks, helped reduce serious asthma flare-ups in children aged 6 to 11 with moderate-to-severe asthma that wasn't well controlled. Researchers found that children who were allergic to many things saw their flare-ups drop by about 60%, while those allergic to just one thing saw a drop of about 75%, compared to children who received a dummy treatment. This appears to be a new finding about how well this treatment works across different groups of children, regardless of how many allergens — things like dust or pet dander that can trigger allergic reactions — affect them.
Ask your doctor: Ask the doctor whether dupilumab might help control the patient's asthma better, especially if the patient has allergies or high IgE levels.
What's New
PubMed · October 1, 2026
Researchers found that adults with asthma from lower-income communities who used a smartphone self-management app were more likely to stop participating in the study early — especially if they had other health conditions alongside their asthma, or had some college education compared to those with a high school diploma or less. On the bright side, people who used the app more in the early weeks tended to stay more engaged over the full year, suggesting that getting people hooked early could be key to keeping them involved. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 1, 2026
Researchers found that biologic medications — a type of injectable drug used for severe asthma — reduced serious asthma flare-ups by roughly half, both in carefully controlled studies and in real-world patients. Interestingly, people who would typically be left out of clinical trials (such as those with a smoking history) still benefited from these medications in the real world, suggesting the strict rules used to select trial participants may cause researchers to miss important information about how well treatments work for a broader group of patients. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 30, 2026
Researchers found that eating a lot of sugar is consistently linked to a higher risk of 18 different health problems, with the strongest evidence connecting sugar intake to type 2 diabetes, obesity, serious heart problems like heart attacks or strokes, and early death. For people with type 2 diabetes especially, this matters because sugar consumption may worsen blood sugar control and raise the chances of complications beyond diabetes alone. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 7, 2026
Researchers found that a type of medication called biologics — which are specialized drugs that target specific parts of the immune system — may help some people with asthma who are critically ill in the intensive care unit and not responding to standard treatments. In the cases reviewed, drugs like benralizumab and omalizumab were given early during ICU stays, often within the first five days, and showed promising results in some of the most severe asthma attacks imaginable. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 2, 2026
Researchers found that in northern China, dangerous spikes in asthma attacks during thunderstorms appear to be linked to mugwort — a common wild plant — rather than the grass pollen that typically triggers these events in Australia and Europe. What makes this especially striking is that many people who ended up in the hospital during these episodes had never been told they had asthma before, meaning they had no idea they were at risk. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a structured self-management program — where people with chronic conditions like type 2 diabetes learn skills to manage their health day-to-day — led to lasting improvements in sleep, pain, fatigue, and mood, even six months after the program ended, across many different countries. For someone with type 2 diabetes, this matters because managing a long-term condition involves a lot more than just medication — things like energy levels, sleep, and emotional well-being all affect how well someone can stay on top of their health. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · September 1, 2026
The text describes a systematic review — a study that gathered and compared existing guidelines — but does not clearly name a specific medical society or authoritative body issuing the recommendations, so it cannot be presented as a single organization's guidance. The review found that most guidelines for people with COPD (a lung disease that makes breathing difficult) consistently recommended at least 150 minutes of moderate physical activity per week, such as brisk walking or cycling, though detailed, condition-specific advice was often limited.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.